易华录(300212) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥412,964,672.37, representing a 34.78% increase compared to ¥306,396,387.56 in the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was -¥28,875,743.27, an improvement of 50.76% from -¥58,647,130.21 in the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥38,437,869.06, showing a 57.79% improvement from -¥91,062,312.85 in the same period last year[4] - The basic earnings per share for Q3 2022 was -0.0438, a 50.79% improvement from -0.089 in the same period last year[5] - Total operating revenue for Q3 2022 was CNY 1,314,385,769.94, a decrease of approximately 17.8% compared to CNY 1,599,427,991.28 in the same period last year[20] - The company reported a total comprehensive income of CNY 4.12 million for Q3 2022, compared to a loss of CNY 2.29 million in Q3 2021[22] - Net profit attributable to shareholders of the parent company for Q3 2022 was CNY -12.79 million, compared to CNY -10.79 million in Q3 2021, indicating a worsening loss[22] - The total operating costs for Q3 2022 were CNY 1.618 billion, compared to CNY 1.375 billion in Q3 2021, an increase of approximately 17.7%[21] Cash Flow - The net cash flow from operating activities for the period was ¥573,741,426.50, a significant increase of 270.99% compared to -¥335,543,448.51 in the same period last year[5] - Cash flow from operating activities for the period was CNY 1.763 billion, down from CNY 1.973 billion in the same period last year, a decrease of about 11%[23] - The net cash flow from operating activities was 573,741,426.50 CNY, a significant improvement compared to -335,543,448.51 CNY in the previous year[24] - Total cash inflow from operating activities amounted to 2,049,211,506.82 CNY, while cash outflow was 1,475,470,080.32 CNY[24] - The net cash flow from investing activities was -366,800,441.90 CNY, an improvement from -882,294,353.38 CNY year-over-year[24] - Cash paid for investment activities was 439,536,580.73 CNY, down from 1,214,848,466.00 CNY in the previous year[24] - The company reported a net increase in cash and cash equivalents of 15,695,894.95 CNY, contrasting with a decrease of -573,010,732.39 CNY in the same period last year[25] - The ending balance of cash and cash equivalents was 257,432,087.37 CNY, up from 440,095,046.63 CNY year-over-year[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,293,220,811.94, a decrease of 0.68% from ¥14,390,704,672.21 at the end of the previous year[5] - Current assets totaled CNY 8,602,113,348.12 as of September 30, 2022, down from CNY 8,877,300,917.57 at the beginning of the year, representing a decline of about 3.1%[19] - Total liabilities amounted to CNY 9,747,396,770.35, slightly down from CNY 9,848,997,399.96, a decrease of approximately 1.0%[19] - The company's total equity increased slightly to CNY 4,545,824,041.59 from CNY 4,541,707,272.25, reflecting a marginal increase of about 0.1%[19] - The company's total assets were CNY 14,293,220,811.94, a decrease from CNY 14,390,704,672.21, representing a decline of approximately 0.7%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,763[13] - The largest shareholder, China Hualu Group Co., Ltd., holds 34.41% of the shares, totaling 229,124,004 shares[13] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest individual shareholder, Lin Yongjun, owning 4.24%[13] - The company has a total of 42,019,972 restricted shares, with 610,155 shares released during the reporting period[16] Research and Development - The company's development expenditure increased to ¥258,362,496.30, a 37.07% rise from ¥188,485,048.66 in the same period last year, indicating increased investment in R&D[10] - R&D expenses fell by 46.98% to approximately CNY 42.54 million, primarily due to changes in the scope of consolidation and organizational adjustments[12] - Research and development expenses decreased to CNY 42.54 million in Q3 2022 from CNY 80.23 million in Q3 2021, a reduction of approximately 47%[21] Government Subsidies and Other Income - The company reported a total of ¥20,309,026.44 in government subsidies for the current period, contributing to its financial performance[8] - Other income increased by 88.52% to approximately CNY 55.34 million, mainly due to an increase in government subsidies recognized this year[12] - Other income increased to CNY 55.34 million in Q3 2022 from CNY 29.36 million in Q3 2021, an increase of about 88%[21] Borrowings and Financial Expenses - The company’s short-term borrowings decreased by 50.70% to ¥1,196,098,109.01, reflecting timely repayment of due loans[10] - Long-term loans decreased by 51.53% to approximately CNY 607.80 million due to timely repayment of due loans[12] - The company experienced a significant increase in financial expenses, totaling CNY 195.94 million in Q3 2022, compared to CNY 206.35 million in Q3 2021, a decrease of about 5%[21] Impairment Losses - Credit impairment losses increased by 241.83% to approximately CNY 50.09 million, reflecting improved collection efforts and reduced bad debt provisions[12] - Asset impairment losses rose by 760.30% to approximately -CNY 7.43 million, in line with new revenue standards and expected credit loss models[12] Audit Information - The company did not conduct an audit for the third quarter report[26]